Clinical Trials Logo

Amyloid Neuropathies, Familial clinical trials

View clinical trials related to Amyloid Neuropathies, Familial.

Filter by:

NCT ID: NCT02939820 Approved for marketing - Clinical trials for Amyloidosis, Hereditary

Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hATTR).

NCT ID: NCT02713880 Withdrawn - Clinical trials for Transthyretin Amyloidosis

Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)

BioTRAP
Start date: August 20, 2018
Phase:
Study type: Observational

International, multicenter, observational, longitudinal study to identify biomarker/s for the development of a new MS-based biomarker for the early and sensitive diagnosis of Transthyretin-Related Familial Amyloidotic Polyneuropathy from blood and number of correctly identified patients with Transthyretin-Related Familial Amyloidotic Polyneuropathy

NCT ID: NCT02595983 Completed - ATTR Amyloidosis Clinical Trials

The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant

Start date: October 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the safety and effectiveness of revusiran (ALN-TTRSC) in adults with transthyretin-mediated amyloidosis (ATTR), whose disease has continued to worsen after liver transplantation. Dosing has been discontinued; patients are being followed-up for safety.

NCT ID: NCT02319005 Completed - Clinical trials for Amyloidosis, Hereditary

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Start date: December 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the safety and efficacy of revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated Familial Amyloidotic Cardiomyopathy. Dosing has been discontinued; patients are being followed-up for safety.

NCT ID: NCT02191826 Completed - Clinical trials for Familial Amyloid Polyneuropathy (FAP)

Study of SOM0226 in Familial Amyloid Polyneuropathy

Start date: July 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Clinical proof of concept study to evaluate SOM0226 efficacy in TTR Amyloidosis.

NCT ID: NCT02175004 Completed - Amyloidosis Clinical Trials

Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

Start date: June 26, 2014
Phase: Phase 3
Study type: Interventional

This study evaluates the safety and tolerability of extended dosing with IONIS-TTR Rx in patients with Familial Amyloid Polyneuropathy.

NCT ID: NCT02016365 Completed - Cardiomyopathy Clinical Trials

Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis

Dox/Urso
Start date: February 2012
Phase: Phase 2
Study type: Interventional

The primary objective for this study is to evaluate the efficacy of doxycycline + ursodeoxycholic acid (UDCA) on disease progression in Transthyretin Amyloidosis (ATTR) subjects with cardiomyopathy with or without neuropathy.

NCT ID: NCT01960348 Completed - Clinical trials for Amyloidosis, Hereditary

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Start date: November 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis. An open-label, single-arm, long-term follow-up extension study NCT02510261 (ALN-TTR02-006) was initiated to provide participants who completed this study with continued patisiran-LNP (lipid nanoparticle) treatment.

NCT ID: NCT01737398 Completed - Amyloidosis Clinical Trials

Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy

Start date: March 15, 2013
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of inotersen given for 65 weeks in participants with Familial Amyloid Polyneuropathy (FAP).

NCT ID: NCT01623245 Completed - Cardiac Amyloidosis Clinical Trials

Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy

Amylo
Start date: June 2012
Phase:
Study type: Observational

Cardiac amyloidosis are related to the accumulation of fibrillar proteins in the extracellular leading to disruption of the cardiac tissue architecture. Amyloidosis in transthyretin (TTR) are the most common hereditary amyloidosis but remain poorly studied at heart. This is serious and deadly. The prevalence of TTR amyloidosis is probably underestimated in hypertrophic cardiomyopathy (HCM) often of unknown etiology because of the lack of systematic implementation of myocardial biopsy because of their side effects.